INDEPENDENT SCIENTIFIC CONSULTING · SAN FRANCISCO BAY AREA BASED · INTERNATIONAL SERVICES
Supporting biotechnology companies and academic research teams with preclinical in-vivo pharmacology and translational biomarker strategies to advance scientific research and drug development.
Specialized services for biotech programs and academic laboratories.
Preclinical pharmacology, translational biomarkers, and scientific program support for drug discovery and development teams.
Focus: in-vivo pharmacology and translational biomarker strategy, with pharmacology contributions to IND-enabling activities — not clinical development services.
Experimental research support and academic-to-industry translation for laboratories seeking rigorous, actionable scientific guidance.
I am a neuroscientist and independent scientific consultant with over 17 years of research experience spanning neuroscience, aging biology, and biotechnology drug development.
My scientific career began in academic research, investigating the molecular mechanisms of brain aging and neurodegeneration. Following my PhD in neuroscience in Paris, I conducted postdoctoral research at the University of California, San Francisco (UCSF), focusing on brain aging, epigenetics, and age-related cognitive decline. My research contributed to understanding the role of Tet2 in adult neurogenesis and cognitive function, resulting in a first-author publication in Cell Reports (2018). I also contributed to research on circulating factors mediating the beneficial effects of exercise on the aging brain, published in Science (2020).
I subsequently transitioned into biotechnology, contributing to drug discovery and preclinical development programs targeting neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia, as well as metabolic diseases such as obesity and MASH. My experience spans small molecules and antisense oligonucleotides (ASOs), with a focus on in-vivo pharmacology, preclinical PK/PD, and translational biomarkers.
At Verge Genomics, I built and led the in-vivo PK/PD pharmacology function and served as a translational biomarker lead, working closely with cross-functional teams to advance preclinical programs and support drug candidate selection. A key contribution was the development and validation of GPNMB as a translational pharmacodynamic biomarker for PIKfyve inhibition in ALS, bridging preclinical studies and early clinical development. This work resulted in a co-first-author publication in Clinical and Translational Science (2026).
Today, I work as an independent scientific consultant, supporting biotech companies and academic laboratories with preclinical pharmacology strategy, translational biomarker development, and data-driven decision-making.
Languages: French (native), English (fluent).
Physiology, neuroscience, and aging biology.
Brain aging, epigenetics, and regenerative mechanisms.
Preclinical neurodegeneration research and therapeutic programs using antisense oligonucleotides (ASOs).
In-vivo pharmacology, PK/PD, biomarkers, and preclinical program leadership focusing on neurodegenerative and metabolic diseases using small molecules.
Preclinical pharmacology and translational support for biotech and academia.
Selected examples from preclinical drug development, biomarker translation, and neuroscience research.
Contributions to preclinical small-molecule programs across neurological and metabolic diseases, integrating in-vivo pharmacology, PK/PD, efficacy, and biomarker evidence to inform program decisions.
Public-facing description; confidential results and internal milestones are not disclosed.
Development of pharmacodynamic biomarker strategies, including GPNMB as a translational readout of PIKfyve inhibition, connecting preclinical models and clinical biomarker evaluation.
Research investigating mechanisms of brain aging, epigenetic regulation, and neurodegeneration.
Explore the full record of research articles, reviews, and a manuscript under review.
All publicationsAvailable to work with biotechnology companies and academic laboratories across the US and internationally. Based in the San Francisco Bay Area.
Connect on LinkedIn